



AHCL/ SE/ 50/2024-25

February 12, 2025

The National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031	BSE Limited Department of Corporate Services 1 st Floor, P.J. Towers, Dalal Street, Mumbai 400 001 ISIN: INE098F01031
Symbol: AMRUTANJAN	Scrip Code: 590006

Dear Sir / Madam,

Sub: Outcome of the Board Meeting

In terms of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today **February 12, 2025** had inter-alia:

- (i) Approved the Unaudited Financial Results for the quarter ended December 31, 2024, as recommended by the Audit Committee at its meeting held on February 12, 2025. The same along with the Limited Review Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.
- (ii) Declared Second Interim Dividend of Re.1/- per share for the financial year 2024-25 on the Equity Shares of the Company.

The Board Meeting commenced at 12:00 P.M and concluded at 4.45 P.M. Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For **Amrutanjan Health Care Limited**

(M Srinivasan)
Company Secretary & Compliance Officer

Encl:

1. Un-audited Standalone Financials Results for the quarter ended December 31, 2024
2. Limited Review Report

AMRUTANJAN HEALTH CARE LIMITED

CIN No : L24231TN1936PLC000017

Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Statement of Unaudited Financial Results for the quarter and nine months ended 31 December 2024

(Amount in INR Lakhs)

Particulars	Quarter ended			Period ended		Year ended
	31 December 2024 (Unaudited)	30 September 2024 (Unaudited)	31 December 2023 (Unaudited)	31 December 2024 (Unaudited)	31 December 2023 (Unaudited)	31 March 2024 (Audited)
I Revenue from operations	12,275.15	10,991.52	11,699.37	31,640.27	29,416.83	42,123.05
II Other income	436.03	404.71	376.39	1,285.94	1,139.77	1,634.83
III Total income (I + II)	12,711.18	11,396.23	12,075.76	32,926.21	30,556.60	43,757.88
IV Expenses						
(a) Cost of materials consumed	2,597.92	1,815.82	2,874.62	6,564.72	7,440.38	10,336.27
(b) Purchase of stock-in-trade	3,045.56	3,448.44	2,715.61	9,224.86	7,525.80	10,630.94
(c) Changes in inventories of finished goods, work-in progress and stock-in-trade	(63.56)	176.44	66.99	(368.23)	(156.56)	215.47
(d) Employee benefits expense	1,470.27	1,452.33	1,204.98	4,308.54	3,522.97	4,769.36
(e) Finance cost	5.59	5.54	5.42	17.59	10.78	15.67
(f) Depreciation and amortisation expense	166.39	165.27	157.65	490.39	452.29	605.69
(g) Other expenses						
Advertisement and selling expenditure	1,656.16	1,490.37	1,362.91	4,023.31	3,722.11	5,242.28
Others	1,233.93	1,247.99	1,316.94	3,837.20	3,804.68	5,747.60
Total expenses (IV)	10,112.26	9,802.20	9,705.12	28,098.38	26,322.45	37,563.28
V Profit before tax (III - IV)	2,598.92	1,594.03	2,370.64	4,827.83	4,234.15	6,194.60
VI Tax expense	674.35	414.47	625.69	1,262.14	1,102.79	1,697.34
VII Profit after tax (V - VI)	1,924.57	1,179.56	1,744.95	3,565.69	3,131.36	4,497.26
VIII Other comprehensive income / (loss)						
Items that will not be reclassified subsequently to profit or loss						
Re-measurement gain/(loss) on defined benefit plans, net of taxes	(56.57)	(39.90)	(24.27)	(100.41)	(1.46)	20.11
Income tax relating to items that will not be reclassified to profit or loss	14.24	10.04	5.37	25.27	(0.37)	(5.06)
Other comprehensive income/ (loss) for the period / year, net of taxes	(42.33)	(29.86)	(18.90)	(75.14)	(1.83)	15.05
IX Total comprehensive income for the period / year (VII + VIII)	1,882.24	1,149.70	1,726.05	3,490.55	3,129.53	4,512.31
Equity share capital (Face value of INR 1/- each, fully paid up)	289.11	289.11	289.11	289.11	289.11	289.11
Other equity						28,559.72
Earnings per equity share						
Basic earnings per share (INR)	6.66	4.08	6.05	12.33	10.79	15.50
Diluted earnings per share (INR)	6.66	4.08	6.04	12.33	10.78	15.50
	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
<i>See accompanying notes to unaudited financial results</i>						



Handwritten signature in blue ink.

AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Notes:

- The above unaudited financial results for the quarter and nine months ended 31 December 2024 in respect of **Amrutanjan Health Care Limited** ('the Company') has been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 12 February 2025. The above unaudited financial results have been subjected to limited review by the statutory auditors of the Company. The auditors have issued an unmodified review report.
- These unaudited financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Company does not have any subsidiary/associate/joint venture company(ies) and hence there is no requirement to prepare Consolidated Financial Results.
- Interim Dividend of INR 1/- per share, aggregating to INR 289.11 Lakhs has been paid during the quarter ended 31 December 2024.
- During the financial year 2020-2021, Amrutanjan's Board of Directors had approved the Amrutanjan Health Care Limited Employee stock option scheme ('Scheme 2020') for the grant of stock options to the employees of the Company. The Compensation Committee administers the plan through a trust established specifically for this purpose, called **Amrutanjan Health Care Limited ESOP trust** ('ESOP trust'). The assets and liabilities of the trust is accounted for as assets and liabilities of the Company on the basis that the trust is exclusively set up for the purpose of administering the ESOP plan of the Company. Further, based on the recommendation of the Compensation Committee, the Board of Directors of the Company has approved further grants under the scheme mentioned above, at its meeting held on 23 May 2024.
- The unaudited financial results of the Company for the quarter and nine months ended 31 December 2024 have been filed with the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) and are available in Company's website www.amrutanjan.com.
- Segment reporting in the unaudited financial results:** Based on the 'management approach' as defined in Ind AS 108 'Operating Segments', the Chief Operating Decision Maker evaluates the Company's performance as OTC Products, Women's Hygiene, Beverages and Other segments (represents Pain Management Centre). With effect from 1 April 2024, 'OTC Products' segment has been split into 'OTC Products' and 'Women's Hygiene'. Comparative information has been presented accordingly.

Particulars	Quarter ended			Period ended		(Amount in INR Lakhs)
	31 December 2024	30 September 2024	31 December 2023	31 December 2024	31 December 2023	Year ended
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	31 March 2024
1 Segment revenue						
a OTC Products	8,793.34	7,325.82	8,243.58	20,724.65	19,702.90	27,513.44
b Women's Hygiene	2,992.59	3,300.10	2,935.68	8,950.70	7,499.22	10,525.88
c Beverages	441.67	338.86	518.32	1,876.04	2,131.58	3,998.11
d Others	47.55	26.74	1.79	88.88	83.13	85.62
Total	12,275.15	10,991.52	11,699.37	31,640.27	29,416.83	42,123.05
2 Segment results						
a OTC Products	2,396.20	1,571.96	2,422.73	4,531.16	4,242.04	6,171.60
b Women's Hygiene	(47.14)	(145.46)	(328.74)	(213.82)	(724.26)	(1,077.25)
c Beverages	(28.26)	(124.64)	53.42	(277.96)	(65.85)	101.56
d Others	(16.47)	(13.19)	(6.59)	(58.71)	(76.03)	(93.60)
Total	2,304.33	1,288.67	2,140.82	3,980.67	3,375.90	5,102.31
Less: Finance cost	5.59	5.54	5.42	17.59	10.78	15.67
Add: Interest income net of other unallocable expenditure	300.18	310.90	235.24	864.75	869.03	1,107.96
Total profit before tax	2,598.92	1,594.03	2,370.64	4,827.83	4,234.15	6,194.60
3 Segment assets						
a OTC Products	6,843.98	6,528.80	7,814.19	6,843.98	7,814.19	7,126.75
b Women's Hygiene	3,664.16	2,195.38	1,704.41	3,664.16	1,704.41	1,902.00
c Beverages	2,391.71	2,416.69	2,223.05	2,391.71	2,223.05	3,524.46
d Others	115.08	119.43	66.95	115.08	66.95	92.80
e Unallocated assets	26,277.31	26,999.20	24,252.29	26,277.31	24,252.29	24,041.06
Total	39,292.24	38,259.50	36,060.89	39,292.24	36,060.89	36,687.07
4 Segment liabilities						
a OTC Products	5,453.53	5,309.99	6,240.65	5,453.53	6,240.65	4,615.57
b Women's Hygiene	1,215.97	1,206.86	938.91	1,215.97	938.91	1,245.85
c Beverages	508.28	425.38	625.82	508.28	625.82	1,198.39
d Others	40.01	48.80	0.00	40.01	-	1.15
e Unallocated liabilities	665.32	1,489.65	616.57	665.32	616.57	777.28
Total	7,883.11	8,480.68	8,421.95	7,883.11	8,421.95	7,838.24
Total capital employed in the Company	31,409.13	29,778.82	27,638.94	31,409.13	27,638.94	28,848.83

For Amrutanjan Health Care Limited



S Sambhu Prasad

S Sambhu Prasad
Chairman & Managing Director
DIN: 00015729

Date: 12 February 2025
Place: Chennai

B S R & Co. LLP

Chartered Accountants

KRM Tower, 1st and 2nd Floors
No. 1, Harrington Road, Chetpet
Chennai – 600 031, India
Telephone: +91 44 4608 3100
Fax: +91 44 4608 3199

Limited Review Report on unaudited financial results of Amrutanjan Health Care Limited for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Amrutanjan Health Care Limited

1. We have reviewed the accompanying Statement of unaudited financial results of **Amrutanjan Health Care Limited** (hereinafter referred to as "the Company") for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 ("the Statement") in which are included unaudited financial results of Amrutanjan Health Care Limited ESOP Trust ("ESOP Trust").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

R Kalyana Sundara Rajan

Partner

Membership No.: 221822

UDIN:25221822BMMKDD7185

Chennai

12 February 2025

Registered Office:

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063